(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Spero Therapeutics's revenue in 2025 is $40,549,000.On average, 3 Wall Street analysts forecast SPRO's revenue for 2025 to be $1,465,385,063, with the lowest SPRO revenue forecast at $1,407,918,982, and the highest SPRO revenue forecast at $1,508,484,624. On average, 3 Wall Street analysts forecast SPRO's revenue for 2026 to be $45,972,865, with the lowest SPRO revenue forecast at $44,170,007, and the highest SPRO revenue forecast at $47,325,008.
In 2027, SPRO is forecast to generate $183,891,459 in revenue, with the lowest revenue forecast at $176,680,029 and the highest revenue forecast at $189,300,031.